Evenamide: A Potential Pharmacotherapeutic Alternative for Treatment-Resistant Schizophrenia

Raghunath Singh¹, Margaret K Hahn^{1

2

3

4}, Yashika Bansal⁵, Sri Mahavir Agarwal^{1

2

3

4}, Gary Remington^{1

2

3}

Affiliations

¹ Schizophrenia Division, the Centre for Addiction and Mental Health, Toronto, ON, Canada.
² Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada.
³ Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
⁴ Banting and Best Diabetes Centre, University of Toronto, Toronto, ON, Canada.
⁵ Neurobiology of Depression and Aging Lab, the Centre for Addiction and Mental Health, Toronto, ON, Canada.

Raghunath Singh et al. Int J Neuropsychopharmacol. 2024.

. 2024 Feb 1;27(2):pyae005.

doi: 10.1093/ijnp/pyae005.

Raghunath Singh¹, Margaret K Hahn^{1

2

3

4}, Yashika Bansal⁵, Sri Mahavir Agarwal^{1

2

3

4}, Gary Remington^{1

2

3}

¹ Schizophrenia Division, the Centre for Addiction and Mental Health, Toronto, ON, Canada.
² Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada.
³ Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
⁴ Banting and Best Diabetes Centre, University of Toronto, Toronto, ON, Canada.
⁵ Neurobiology of Depression and Aging Lab, the Centre for Addiction and Mental Health, Toronto, ON, Canada.

No abstract available

References

1. Anand R, Forrest EC, Hartman RD, Graham SM, Faravelli L (2017) Evenamide, a voltage-gated sodium channel blocker in the treatment of schizophrenia: results from a placebo-controlled study. Eur Neuropsychopharmacol 27:S947–S948.
1. Anand R, Forrest EC, Hartman RD, Graham SM, Faravelli L (2018) T48 Antipsychotic efficacy of evenamide (nw-3509) is due to modulation of glutamatergic dysregulation. Schizophr Bull 44:S132–S132.
1. Anand R, Turolla A, Chinellato G, Roy A, Hartman RD (2023) Phase 2 results indicate evenamide, a selective modulator of glutamate release, is associated with remarkable clinically important long-term efficacy when added to an antipsychotic in patients with treatment-resistant schizophrenia (TRS). Int J Neuropsychopharmacol 26:pyad035. - PMC - PubMed
1. Bortolato M, Faravelli L, Anand R (2018) T36 The antipsychotic-like properties of evenamide (nw-3509) reflect the modulation of glutamatergic dysregulation. Schizophr Bull 44:S126–S127.
1. Faravelli L, Anand R, Forrest E (2016) Evenamide (formerly NW-3509) targets new mechanisms, and represents a new approach to the management of untreated symptoms in schizophrenia. Eur Neuropsychopharmacol 26:S588.